- Home
- CTO vs LXRX Comparison
CTO vs LXRX Comparison
Compare CTO & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CTO | LXRX |
|---|---|---|
| Founded | 1902 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.9M | 447.0M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | CTO | LXRX |
|---|---|---|
| Price | $18.35 | $1.15 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $22.00 | $3.23 |
| AVG Volume (30 Days) | 321.3K | ★ 1.7M |
| Earning Date | 02-19-2026 | 11-06-2025 |
| Dividend Yield | ★ 8.39% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $146,948,000.00 | $70,864,000.00 |
| Revenue This Year | $20.87 | $56.61 |
| Revenue Next Year | $4.29 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 23.84 | ★ 1255.21 |
| 52 Week Low | $15.07 | $0.28 |
| 52 Week High | $20.88 | $1.66 |
Technical Indicators
Market Signals| Indicator | CTO | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.78 | 37.29 |
| Support Level | $18.01 | $1.11 |
| Resistance Level | $18.45 | $1.24 |
| Average True Range (ATR) | 0.33 | 0.07 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 73.46 | 15.22 |
Price Performance
Historical ComparisonAbout CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.